Breaks Categories: Stock Spotlights

MondayDec 11, 2017 5:16 pm

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Develops Cannabis-Based Therapeutics in Response to Opioid Epidemic

Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is using scientific research and development to stake out its spot in the medical marijuana industry. An article discussing this reads: “Veritas Pharma’s mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company’s approach, combined with its strategic alliances, will effectively address the medical community’s concerns over the complexities of cannabis potency, efficacy, quality and content in the…

Continue Reading

MondayDec 11, 2017 3:53 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Utilizes Proprietary Advanced Biosynthesis Process to Develop Cannabinoids-based Therapies

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) remains focused on discovering potential breakthrough cannabinoid-based therapies by utilizing its proprietary cannabinoid biosynthesis process and its bioinformatics drug and disease targeting tool. An article discussing this reads: “Other biopharmaceutical companies may produce cannabinoids in the laboratory using chemical synthesis, but there’s a litany of drug development efforts with synthetic molecules that have failed. The proprietary biosynthesis process used by InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) is unique. Producing cannabinoids that are identical to naturally occurring compounds is transformative for drug development. By using its proprietary process, InMed is able to manufacture exact…

Continue Reading

MondayDec 11, 2017 3:39 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sets its Sights on Booming Global Cannabis Industry

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) patented delivery technology, DehydraTECH™ has positioned the company at the forefront of the thriving global cannabis industry. A recent article discussing this reads: “LXRP’s technology enables improved delivery of bioactive substances via oral ingestion that results in increased absorption without the need for unhealthy practices of inhalational dosing that result in damaging affects to the lungs. The technology also eliminates the need for co-administration with unhealthy sugars or sweeteners in delivery that are commonly used to mask the bitter tastes. With DehydraTECH™, bioactive substance delivery is improved by combining molecules with certain fatty acids…

Continue Reading

FridayDec 08, 2017 12:42 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTech™ Shines in Vegas Lights

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) attracted a lot of attention in Las Vegas at this year’s Marijuana Business Conference & Expo due to increased awareness about potential health benefits of cannabinoids and an increased demand for improved CBD-based edibles. A recent article highlights keen interest in Lexaria’s patented DehydraTECH™ delivery technology, stating, “Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids,…

Continue Reading

WednesdayDec 06, 2017 3:28 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Featured in Visual Capitalist Company Spotlight

Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) was recently highlighted in a company spotlight article by Visual Capitalist. The article features an infographic that breaks down the company’s development of novel cannabinoid-based therapies from start to finish. Among other areas of interest, Visual Capitalist provided an in-depth look into InMed's Bioinformatics assessment tool, Biosynthesis cannabinoid manufacturing process, and drug pipeline of new cannabinoid treatments. To view the full infographic, visit http://cnw.fm/5afgV About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery…

Continue Reading

MondayDec 04, 2017 1:10 pm

CannabisNewsBreaks – Cannabis Demand in Canada Creates Considerable Opportunity for ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

As Canada prepares for the legalization of recreational marijuana in July 2018, analysts are noting a shortage of supplies compared to expected demand for cannabis products. The demand is expected to exceed about 1.3 million pounds, easily outpacing current annual production of 20,000 pounds by the country’s licensed producers. That creates tremendous opportunities for Canada’s top cultivators with the ability to expand their operations and increase supply. An article discussing this reads: “ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), has been licensed in good standing since 2014 with no history of product recalls, and proprietary computer-controlled production systems that have bolstered…

Continue Reading

TuesdayNov 21, 2017 12:10 pm

CannabisNewsBreaks – Medical Cannabis Supplier ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Keeps Pricing Competitive

Medical cannabis products distributed by Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) in Canada are building on the organic growing environment in any given geographical climate to provide consistent quality while keeping costs down. An article discussing this reads: “As one of Canada’s first licensed cannabis producers, Abcann is significantly ahead of the curve when it comes to production capacities. The company’s Vanluven Facility, producing 1,000 kg annually, is licensed and fully operational, with an additional bloom chamber being added. Construction on the Kimmett facility, an industry-leading, purpose-built, world class style facility, is under contract with another 65 acres under…

Continue Reading

ThursdayNov 09, 2017 10:00 am

CannabisNewsBreaks – Wildflower Brands Inc.’s (CSE: SUN) (OTCQB: WLDFF) CBD+ Capsules Featured Amongst Best Products on Hightimes.com Article

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) was highlighted in an article titled, ‘10 Best CBD Products Of 2017’ authored by Chloé Harper Gold on Hightimes.com. Wildflower's CBD+ Capsules were featured in the article, highlighting the ease of the mess-free capsules which appeals to consumers who seek the full benefit of CBD without the vaporizers. Each capsule contains 30 mg of CBD, amino acids, Omega 3, Omega 6, and hemp-seed oil. The convenience of the capsules makes for a fast and easy approach at incorporating CBD into a daily routine. CBD+ Capsules are available for purchase on the company's website (http://cnw.fm/iDx8v).…

Continue Reading

WednesdayNov 08, 2017 12:53 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Enters the Multibillion-Dollar Tea Market

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed delivery technologies to improve absorption of bioactive compounds and intends to use that technology in the tea market. The company plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. An article discussing this reads: “Lexaria’s acquisition of Poviva Tea, LLC, announced on November 2 (http://cnw.fm/An29S), gives Lexaria a toehold in this vast $7 billion-plus market and consolidates ownership of Poviva Tea, LLC as a wholly owned Lexaria Bioscience subsidiary. The move also simplifies future operations and certain intellectual property ownership issues.…

Continue Reading

FridayNov 03, 2017 12:16 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Unlocks Ability to Produce 90+ Cannabinoids through Biosynthesis

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues to advance its drug development programs through the use of its proprietary bioinformatics database assessment tool. An article discussing this reads: “InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids (http://cnw.fm/hFe3o). The company recently announced it has enabled the production of all four “gateway” cannabinoids using genetically engineered microorganisms. From these gateway substrates, production of all 90+ cannabinoids is possible via biosynthesis. InMed’s breakthrough stands to make the production of cannabis derivatives, including THC, CBD…

Continue Reading